Ladies and gentlemen, thank you for standing by and welcome to the Galapagos Conference Call.
I would now like to hand the conference to your speaker today, Elizabeth Goodwin. Please go ahead.
Elizabeth Goodwin
Vice President, Investor Relations
Thank you and welcome all to the audio webcast of Galapagos full year 2020 results. I m Elizabeth Goodwin, Investor Relations, also representing a great reporting team at Galapagos. This recorded webcast is accessible via our website homepage and will be available for download and replay later today.
I would like to remind everyone that we will be making forward-looking statements during today s webcast. These forward-looking statements include remarks concerning future developments of the pipeline in our company and possible changes in the industry and competitive environment because these forward-looking statements involve risks and uncertainties, Galapagos actual results may differ materially from the results expressed or implied
Why the three biggest vaccine makers failed on COVID-19
Hannah Kuchler and Leila Abboud
Feb 18, 2021 â 12.04pm
Save
Share
GlaxoSmithKline, Merck and Sanofi are now left playing catch-up, after upstarts including Moderna and BioNTech demonstrated their mastery of new technologies that will shape the industry for years to come.
The scarcity of vaccines around the world is directly connected to big pharma groups being missing in action.Â
New Jersey-based Merck recently dropped its vaccine development program completely, while Paris-based Sanofi and the UKâs GSK are having to redo an early-stage trial of the jab they are jointly developing, after a dosing mistake.
Covid 19 coronavirus: Why the three biggest vaccine makers failed on Covid-19
16 Feb, 2021 07:05 PM
9 minutes to read
GlaxoSmithKline, Merck and Sanofi are now left playing catch-up in the vaccine race. Photo / 123RF
Financial Times
GlaxoSmithKline, Merck and Sanofi are left playing catch-up to upstarts with new technology. As pharmaceutical companies raced to develop Covid-19 vaccines, crossing the finishing line in record time, the world s three biggest vaccine makers were also-rans.
GlaxoSmithKline, Merck and Sanofi are now left playing catch-up, after upstarts including Moderna and BioNTech demonstrated their mastery of new technologies that will shape the industry for years to come.
New Jersey-based Merck recently dropped its vaccine development programme completely, while Paris-based Sanofi and the UK s GSK are having to redo an early-stage trial of the jab they are jointly developing, after a dosing mistake.